Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]
Future Fields and Jenthera Therapeutics Collaborate to Develop Novel Protein for the Delivery of Cancer Biologics
Future Fields, a pioneering biotechnology company that has built the world’s first synthetic biology system […]
Heligenics Unveils A First-Of-Its-Kind Precision Prescription Test For Breast Cancer Therapeutics
Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs […]
Thales Helps Lunit Accelerate the Growth of AI-based Software Cancer Diagnostic Solutions
Thales, a global leader in software monetization and licensing, is collaborating with Lunit, a global […]
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug
Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals which is a synthetic biology-driven biopharma […]
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
Lantern Pharma, an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary […]
SciTech Development Raises $2.73 Million in Oversubscribed Funding Round to Advance Clinical Trials for Cancer Treatment
SciTech Development has announced it has closed a $2.73M funding round, led by several prominent […]
BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme
BPGbio, a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced […]
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel […]
Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting
Promontory Therapeutics, a clinical-stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more